The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Oncogene

• Publication date

  2010-07-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/onc.2010.137PMID 20473328PMCID PMC4374435
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activated Ras signaling significantly enhances reovirus replication and spread

  2010cited by this paper
• Reovirus infection of cancer cells is not due to activated Ras pathway

  2009cited by this paper
• Induction of Alpha/Beta Interferon by Myxoma Virus Is Selectively Abrogated When Primary Mouse Embryo Fibroblasts Become Immortalized

  2009influential reference
• Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.

  2009cited by this paper
• Myxoma Virus Targets Primary Human Leukemic Stem and Progenitor Cells While Sparing Normal Hematopoietic Stem and Progenitor Cells

  2009cited by this paper
• A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

  2008cited by this paper
• Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.

  2008cited by this paper
• Transcriptional role of p53 in interferon-mediated antiviral immunity

  2008influential reference
• A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

  2008cited by this paper
• Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus

  2007cited by this paper
• Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer

  2007cited by this paper
• Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells

  2007cited by this paper
• Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

  2007cited by this paper
• Protein serine/threonine phosphatase-1 dephosphorylates p53 at Ser-15 and Ser-37 to modulate its transcriptional and apoptotic activities

  2006cited by this paper
• Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma.

  2006cited by this paper
• p53 promotes adenoviral replication and increases late viral gene expression

  2006cited by this paper
• Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor.

  2006influential reference
• Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.

  2005cited by this paper
• Not all viruses are bad guys: the case for reovirus in cancer therapy.

  2005cited by this paper
• Poxvirus tropism

  2005cited by this paper
• The ATM-dependent DNA damage signaling pathway.

  2005cited by this paper
• The preferential cytotoxicity of reovirus for certain transformed cell lines

  2005cited by this paper
• Future prospects for oncolytic therapy

  2005cited by this paper
• Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection.

  2004cited by this paper
• Induction of p53-Dependent Apoptosis in HCT116 Tumor Cells by RNA Viruses and Possible Implications in Virus-Mediated Oncolysis

  2004cited by this paper
• Conditionally Replicating Adenoviruses Kill Tumor Cells via a Basic Apoptotic Machinery-Independent Mechanism That Resembles Necrosis-Like Programmed Cell Death

  2004cited by this paper
• Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.

  2004cited by this paper
• ATP Activates Ataxia-Telangiectasia Mutated (ATM) in Vitro

  2003influential reference
• Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

  2003cited by this paper
• Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence

  2003cited by this paper
• Ras interference as cancer therapy.

  2003cited by this paper
• Role of the Serine-Threonine Kinase PAK-1 in Myxoma Virus Replication

  2003cited by this paper
• A role for p53 in the frequency and mechanism of mutation.

  2002cited by this paper
• Reovirus therapy of lymphoid malignancies.

  2002cited by this paper
• Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression

  1999cited by this paper
• The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

  1998cited by this paper
• Reovirus therapy of tumors with activated Ras pathway.

  1998cited by this paper
• The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection

  1996cited by this paper
• An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells

  1996cited by this paper
• Tumour biology. p53, guardian of Rb.

  1994cited by this paper
• p53, guardian of Rb

  1994cited by this paper
• Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency.

  1993cited by this paper
• Differential sensitivity of normal and transformed human cells to reovirus infection

  1978cited by this paper
• Characteristics of an established cell line of retinoblastoma.

  1974cited by this paper

• Exploring the inherent susceptibility of cancer-associated fibroblasts to oncolytic virus infection

  2026cites this paper
• From infection to remedy: Harnessing oncolytic viruses in cancer treatment.

  2025cites this paper
• The reovirus variant RP116 is oncolytic in immunocompetent models and generates reduced neutralizing antibodies to Type 3 Dearing

  2024cites this paper
• Oncolytic viruses in hematological malignancies: hijacking disease biology and fostering new promises for immune and cell-based therapies.

  2023cites this paper
• Optimal delivery of RNA interference by viral vectors for cancer therapy.

  2023cites this paper
• Cytokine Gene Vaccine Therapy for Treatment of a Brain Tumor

  2023cites this paper
• IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma

  2023cites this paper
• Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer

  2023cites this paper
• Exploring the Mechanism of Action of Qi-angwu, Duhu and Cangzhi in the Treatment of Rheumatoid Arthritis Based on Network Pharmacology

  2023cites this paper
• A novel anti-cancer therapy with nuclear export inhibitor Selinexor in combination with oncolytic myxoma virus

  2022cites this paper
• Distinguishing the pros and cons of metabolic reprogramming in oncolytic virus immunotherapy

  2022cites this paper
• RNA Helicase A/DHX9 Forms Unique Cytoplasmic Antiviral Granules That Restrict Oncolytic Myxoma Virus Replication in Human Cancer Cells

  2021cites this paper
• Oncolytic virus therapy in cancer: A current review

  2021cites this paper
• Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.

  2021cites this paper
• Oncolytic Viruses as Nanomedicines against the Tumor Microenvironment

  2021cites this paper
• Oncolytic virotherapy in hepato‐bilio‐pancreatic cancer: The key to breaking the log jam?

  2020cites this paper
• Oncolytic Virotherapy with Myxoma Virus

  2020cites this paper
• Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs

  2020cites this paper
• Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1

  2020cites this paper
• Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes

  2019cites this paper
• Combination Therapy with Reovirus and ATM Inhibitor Enhances Cell Death and Virus Replication in Canine Melanoma

  2019cites this paper
• Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks

  2019cites this paper
• Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.

  2019cites this paper
• The Akt signaling pathway in skin cancer cell lines treated with RRM-MV, a short peptide analogue of the MT5 protein of myxoma virus

  2018cites this paper
• Herpes Simplex Virus Type 1 for Use in Cancer Gene Therapy: Looking Backward to Move Forward

  2018cites this paper
• Oncolytic virotherapy for the treatment of Non-Hodgkin Lymphoma

  2018cites this paper
• Reovirus safety study for proliferation and differentiation of human adipose-derived mesenchymal stem cells

  2017cites this paper
• “Heat shock protein 70 in pancreatic diseases: Friend or foe”

  2017cites this paper
• Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells

  2017cites this paper
• Herpes Simplex Virus Type 1 for Use in Cancer Gene Therapy : Looking Backward to Move

  2017cites this paper
• Oncolytic viral therapy for pancreatic cancer

  2017cites this paper
• Employing RNA viruses to fight cancer: novel insights into oncolytic virotherapy

  2017cites this paper
• Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition

  2016cites this paper
• Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival.

  2016cites this paper
• Replicating viruses for gynecologic cancer therapy.

  2016cites this paper
• Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies

  2016cites this paper
• Viruses as nanomedicine for cancer

  2016cites this paper
• Optimising Reovirus Type 3 Dearing (Reolysin®) as an anti-cancer therapeutic

  2016cites this paper
• Naturally occurring reoviruses for human cancer therapy

  2015cites this paper
• Reoviral Oncotropism Against c-Myc Overexpressing HS 68 Cells

  2015cites this paper
• Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease.

  2015cites this paper
• PI3K/Akt/p53 pathway inhibits reovirus infection

  2015cites this paper
• Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis

  2015cites this paper
• Combinaison d’approches classiques et de génétique inverse en vue d'une meilleure compréhension du tropisme et de l'activité oncolytique du réovirus de mammifères

  2015cites this paper
• Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells.

  2015cites this paper
• Oncolytic Viruses: Exploiting Cancer's Deal with the Devil.

  2015cites this paper
• Replicating poxviruses for human cancer therapy

  2015cites this paper
• Molecular Determinants for the Inactivation of the Retinoblastoma Tumor Suppressor by the Viral Cyclin-dependent Kinase UL97*

  2015cites this paper
• Low pathogenic human enteroviruses as novel anti-cancer agents against malignant glioma

  2014cites this paper
• Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity

  2014influential citation
• From Scourge to Cure: Tumour-Selective Viral Pathogenesis as a New Strategy against Cancer

  2014cites this paper
• Oncolytic Poxviruses.

  2014cites this paper
• Oncolytic measles virus and mesenchymal stromal cells: A therapeutic model and a dissection of mechanisms of action

  2014cites this paper
• A Whole-Genome RNA Interference Screen for Human Cell Factors Affecting Myxoma Virus Replication

  2013cites this paper
• Molecular Mechanisms of Reovirus Oncolysis

  2013cites this paper
• THE COMBINATION OF CARBOXYLESTERASE-EXPRESSING ONCOLYTIC VACCINIA VIRUS AND IRINOTECAN

  2013cites this paper
• Amino acid substitutions in σ1 and μ1 outer capsid proteins are selected during mammalian reovirus adaptation to Vero cells.

  2013cites this paper
• The p53-microRNA-34a axis regulates cellular entry receptors for tumor-associated human herpes viruses.

  2013cites this paper
• Vaccinia Virus Outperforms a Panel of Other Poxviruses as a Potent Oncolytic Agent for the Control of Head and Neck Squamous Cell Carcinoma Cell Lines

  2013cites this paper
• Oncolytic Reovirus in Canine Mast Cell Tumor

  2013cites this paper
• Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.

  2012cites this paper
• Étude de la protéine sigma 1 de réovirus par génétique inverse

  2012cites this paper
• Oncolytic viruses: smart therapeutics for smart cancers.

  2012cites this paper
• Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy

  2012cites this paper
• A bioactive peptide analogue for myxoma virus protein with a targeted cytotoxicity for human skin cancer in vitro

  2012cites this paper
• High therapeutic potential for systemic delivery of a liposome-conjugated herpes simplex virus.

  2011cites this paper
• Thunder and lightning: immunotherapy and oncolytic viruses collide.

  2011cites this paper
• The current status and future directions of myxoma virus, a master in immune evasion

  2011cites this paper
• Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation

  2011cites this paper
• Oncolytic virotherapy for pancreatic cancer

  2011cites this paper
• Attenuated reovirus displays oncolysis with reduced host toxicity

  2010cites this paper
• reovirus displays oncolysis with reduced host toxicity.

  2010cites this paper